Michael P. Dube - 01 Mar 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
VP, Chief Accounting Officer
Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
01 Mar 2026
Net transactions value
$0
Form type
4
Filing time
03 Mar 2026, 16:15:37 UTC
Previous filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dube Michael P VP, Chief Accounting Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE James Basta, attorney-in-fact 03 Mar 2026 0002019493

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +17,250 +33% $0.000000 69,527 01 Mar 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.